EP3421039

DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR

  • :
    EP einkaleyfi: Þýðing ekki lögð inn
  • :
    24.2.2017
  • :
    6.10.2021
  • :
    17756670.0
  • :
    23.2.2037
  • :
    DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR

24.2.2017
6.10.2021
  • :
    ONO Pharmaceutical Co., Ltd.
  • :
    1-5, Doshomachi 2-chome Chuo-ku, Osaka-shi, Osaka 541-8526, JP
  • :
    TANAKA, Kohei
  • :
    Mishima-gun Osaka 618-8585, JP
  • :
    YASUHIRO, Tomoko
  • :
    Mishima-gun Osaka 618-8585, JP
  • :
    2016035206
  • :
    26.2.2016
  • :
    JP
  • :
    JP2017007219
  • :
    24.2.2017
  • :
    A61K 31/4709, A61K 39/395, A61K 45/00, A61P 35/00, A61P 43/00, C07K 16/18